Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia

NCT00813826 is registered in ClinicalTrials.gov with Solace Pharmaceuticals as lead sponsor.

NCT NCT00813826
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00813826 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study Evaluating the Efficacy and Tolerability of Oral SLC022 300 mg TID, a Glial Cell Modulating Agent, Versus Placebo in the Treatment of Post Herpetic Neuralgia
Lead sponsor
Solace Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
January 31, 2009
Completion date
November 30, 2009
Enrollment
204 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

postherpetic neuralgia